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Abstract 
Background: Adenosine deaminase (ADA) specifications (EC3.5.4.4) is an enzyme is involved in purine 
metabolism that breaks adenosine and deoxy-adenosine and produce inosine and deoxy-inosine and ammonia. The 
highest levels are of adenosine deaminase activity in monocytes and lymphocytes. High serum ADA activity with 
increased serum levels of AST, ALT and immunoglobulins were reported in variety of diseases including hepatitis. 
We aimed to investigate the activity of total ADA in serum of patients with hepatitis B and were determined 
molecular weight ADA1 and ADA2 isozymes in serum and RBC of hepatitis patients. Materials and Methods: 
We were defining experiments by electrophoresis on SDS-PAGE,  for isozymes of ADA; ADA1 and ADA2 in 
serum and red blood cells. ADA1 molecular weight was estimated at about 35 KDa and ADA2 about 110 KDa. The 
total ADA activity was measured by the modified Ellis method in 37 patients with hepatitis B and 40 healthy 
controls in the age range (20-60 years). Results: The normal values for serum ADA in humans have been studied 
by various workers and found in serum samples to be in the range of 0-15 U/L, whiles in our analysis total ADA 
(tADA) enzyme activity is in controls and patients with hepatitis B, respectively, 13.35 ± 1.62 and 27.05 ± 8.49. 
Our results indicated that tADA level was higher in patients with hepatitis B than those of corresponding controls 
(P < 0.05).Total ADA enzyme activity shows a significant increase compared to the control group in all age 
groups tested. Conclusion: Therefore, the serum ADA level could be used as an index along with other parameters 
in follow up of patients with hepatitis B. 
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Hepatitis B is characterized as an 
inflammation of the liver and a potentially life-
threatening liver infection which caused by the 
hepatitis B virus (HBV). It is a major global health 
problem and it can cause chronic infection and puts 
people at high risk of death from cirrhosis and liver 
cancer [1]. The virus is transmitted by exposure to 
blood, semen, or another body fluid of an infected 
person. This can happen through sexual intercourse; 
working in healthcare; tattooing and acupuncture; 
sharing needles, syringes, or other drug-injection 
equipment; or from mother to baby at birth [2]. Viral 
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hepatitis is usually monitored by repeated 
measurements of aminotransferase and viral load 
levels. Quantitation of viral load by polymerase chain 
reaction (PCR) may offer a more reliable marker of 
disease status. About 350 million people are 
chronically infected with hepatitis B. More than 
780,000 people die every year due to complications 
of hepatitis B, including cirrhosis and liver cancer [3, 
4]. Hepatitis B is an important occupational hazard 
for health workers. However, it can be prevented by 
currently available safe and effective vaccine. Most 
people, particularly children, don't experience any 
symptoms during the acute infection phase [5]. 
However, some people have acute illness with 
symptoms that last a few weeks, including yellowish 
skin and eyes (jaundice), dark urine, tiredness, 
vomiting and abdominal pain [6].  
Adenosine deaminase (EC 3.5.4.4) is an amino 
hydrolytic enzyme that is involved in the 
deamination of adenosine and deoxy-adenosine 
nucleosides, forming inosine and deoxy-inosine, 
respectively. ADA is widely distributed in human 
tissues included in spleen, kidney, serum, 
lymphocytes, leucocytes and erythrocytes. In 
particularly, ADA has an important role in 
proliferation and differentiation of lymphocyte cells 
[7-9]. The enzyme is a glycoprotein (molecular 
weight=32.5-33kDa) which contains galactose and 
glucosamine. Optimum PH of 3.6, and the isoelectric 
point of is 4.85. The receptor activator show not been 
reported and no metal ion as a cofactor. The 
deamination specificity is same of the adenosine and 
deoxy-adenosine. In humans, the highest ADA 
activity exists in the thymus and other lymphoid 
tissues (800 IU/ mg) and the lowest activity in 
erythrocytes (1 Iu/ mg). Also, ADA activity in T 
cells are much higher than B cells[10, 11].The 
normal values for serum ADA in humans have been 
studied by various workers and found in serum 
samples to be in the range of 0-15 U/L. pleural fluid, 
values were found to be in the range of 6.8-30 U/L, 
and for CSF , values were found to be in the range of 
<5 U/L [12-14]. altered serum ADA activity were 
reported in portal cirrhosis, acute hepatitis, 
tuberculosis, leishmaniosis, arthritis rheumatoid, 
HIV, hepatitis, jaundice, hematoma and primary 
immunodeficiency [9, 15, 16]. Two ADA isozymes 
are identify as ADA1 and ADA2.The ADA1 isozyme 
is found in all cells, with the highest activity in 
lymphocytes and monocytes, while ADA2 is the 
principal isozyme in the serum of normal subjects. 
Most human cells contain very small amounts of 
ADA2 and its major source is likely to be a monocyte 
macrophage cell system [7]. ADA deficiency in 
humans is an autosomal recessive disorder that results 
in severe combined immunodeficiency disease, ADA 
deficiency caused a widely of diseases, increase or 
decrease the enzyme activity exists in many diseases 
and in some disease-specific isozymes are changed 
[17]. Therefore, the methods and techniques designed 
to measure the ADA as an important complementary 
test to help diagnose many diseases. Since molecular 
weight and activity of these isozymes different with 
each other, it is possible to investigate and isolate them 
in the laboratory. the purpose of this study were to 
determine the serum ADA activity in patients with 
hepatitis and compare with the control group and this 
work shows a method of ADA isozymes detection in 
SDS-PAGE gel electrophoresis.   
 
Methods 
Patients. After confirming a specialist in 
medical center (Tehran Heart Center), we first of 37 
patients with hepatitis B (16 men and 21 women) were 
studied between August 2012 and March 2013. For 
comparison, 40 similar sex and age-matched healthy 
controls were also included in this study. Serum 
samples were then centrifuged at rpm 2500 rpm for 10 
minutes apart in the same way we obtain the serum of 
10 healthy people as well. 
Blood sampling protocol. For accumulation of 
serum, blood was drawn into pyrogen-free tubes 
without additives. The blood was allowed to clot for 1 
hour and centrifuged at 1000× g for 10 min at 4 °C, 
and serum was stored at −80 °C until analyzed. 
Measurement of adenosine deaminase. Total 
serum ADA activity was measured by the modified 
Ellis method[18] with a model 912 type Automatic 
Analyzer (Hitachi Co. Ltd., Tokyo, Japan). ADA assay 
kit is for the determination of ADA activity in human 
serum, plasma samples, CSF and pleural fluid. This kit 
has been prepared based on an enzyme adenosine to 
inosine in the substrate conversion and ammonia is 
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released. In the second stage the ammonia, alpha 
Keto-glutarate and NADPH is converted to glutamate 
and NADP+ by glutamate dehydrogenase, as 
absorption at 340 nm was measured in the sample is 
proportional to the amount of ADA.  The rate of 
absorption at 340 nm will be a direct relationship 
with the ADA enzyme activity. One unit of ADA 
activity is defined as the amount of enzyme that 
converts 1 mM adenosine to inosine and ammonia 
per minute under standard assay conditions and is 
expressed as IU/l. The enzyme is stable for at least 
24 h at 25°C, 7 days at 4°C, and 3 months at -20°C[7, 
18].To minimize the measurement errors all the 
assays were performed two times and the mean value 
is presented. 
 
Preparation of Serum and Lysate of 
Erythrocytes from electrophoresis. A pool of venous 
blood samples was used. The RBC were obtained 
after blood centrifugation 2000 rpm during 10 min at 
4°C. Red blood cells were washed three times in 
saline solution (NaCl 150 mM) and then lysated with 
distilled water (1:3) using a vortex mixer for 5 
minutes. After lysate centrifugation at 2000 rpm (10 
min / 4°C), the supernatant was separated and were 
loaded in SDS-PAGE Gel for electrophoresis 
procedure. An appropriate dilution of the sample to a 
ratio of 1 to 10 and 1 to 50 are produced at a rate of 1 
to 4 to make and loading buffer are added. The SDS-
PAGE gel (8% and 10%) for the electrophoresis was 
prepared in 50 mM phosphate buffer (pH=6.7). A 
100 mM phosphate buffer (pH= 6.7) was used as 
running buffer. The run was performed using 100VFor 
4 hours. The environmental temperature was 
maintained at 4°C. 20 μL of sample were used in each 
well. 
 
Statistical Analysis. All results were described 
in terms of mean ± standard deviation (SD). Statistical 
significance of differences between mean values was 
tested by one way analysis of variance (ANOVA) test. 
All analyses were performed using the Statistical 
Package for the Social Sciences (SPSS, version 23). A 




ADA activity assay. The comparison of 
enzymatic levels in the sera of viral hepatitis cases 
with the control group is shown in the Table 1. As the 
table shows results, ADA enzyme activity in 
comparing the two groups (patients and controls), 
were found to be significantly higher in the cases with 
hepatitis than the controls (p<0.05), but a significant 
amount were obtained in the hepatitis and control 
groups is larger than 0.05, so the tADA no significant 






Table1: Adenosine deaminase activity in hepatitis B Total ADA activity was assayed in serum of healthy control 
and hepatitis B patients. In hepatitis B, the total activity of ADA in serum increased as compared to healthy 
controls. The difference was significant between control and hepatitis B patients (p< 0.001). 
 







Total ADA activity 13.35±1.62 27.05±8.49 
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ADA is the major enzyme of adenosine 
metabolism. It plays a critical role in the 
differentiation and maturation of the immune cells 
including lymphocytes and monocyte-macrophage cell 
lines [7, 8]. An increases in serum ADA activities 
hepatitis B virus infected subjects [9, 19, 20], acquired 
immune deficiency syndrome (AIDS) [21], and other 
Infectious diseases such as tuberculosis, leishmaniosis, 
brucellosis, typhoid fever and human 
immunodeficiency virus infection [22-24], reflect the 
amplified in phagocytic activity of the macrophages 
and may be valuable in monitoring on the 
pathogenesis of hepatitis [9, 25, 26]. There are few 
reports available on ADA levels in hepatitis subjects, 
however, only one of them focused on ADA activity in 
different phases of the disease based on a body of 
experimental proof that revealed importance of ADA 
[15]. In another study, kaya et al, suggested that the 
evaluation of ADA activity in serum of patients with 
hepatitis B and C could be considered as a useful tool 
for monitoring their clinical status, and they reported 
that serum ADA levels were significant higher in HBV 
and HCV patients with high viral load than in controls, 
although there was no statistical difference in the ADA 
levels of HBV and HCV in patients with low viral load 
[27]. In agreement with previous studies, in this survey 
we observed the level of total ADA activity in serum 
with HBV patients clearly higher than in controls, and 
there was no significant difference between men and 
women with hepatitis patient.   
Adenosine and 2'deoxyadenosine are molecules 
with many effects on human cells . Isozymes of ADA; 
ADA1 and ADA2 deaminated inosine and 2'deoxy-
inosine. Thus, the homeostasis of these substances and 
the activity of the isozymes ADA1 and ADA2 in 
human cells are of extreme importance [28-30]. 
The isozyme ADA1 is ubiquitous and 
guarantees the adjustment of the substrates adenosine 
and 2'deoxyadenosine. PH of 7–7.5 and a similar 
affinity for both adenosine and 2'deoxyadenosine. 
These features make ADA1 highly efficient in 
deamination the substrates (adenosine and 
 
 
Figure 1. SDS-PAGE analysis of determined molecular weight 
ADA1 (10% gel).Line 1 Prestained ladder, line 2 to 8 contains 
RBC lysates with HBV patients in the presence of 2-
mercaptoethanol (+2ME), which binds to free SH groups but does 
not alter the electrophoretic mobility of the RBC-ADA isozyme. 
 
 
Figure 2. SDS-PAGE analysis of determined molecular weight 
ADA2 (8% gel). Line 1: Prestained ladder, line 2 to 10 contains 
pool serum with HBV patients in the presence of 2-
mercaptoethanol (+2ME), which binds to free SH groups but 
does not alter the electrophoretic mobility of the serum-ADA 
isozyme. 
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2'deoxyadenosine), whiles the isozyme ADA2 is not 
ubiquitous, but coexists with ADA1 only in 
monocytes-macrophages. ADA2 has an optimum pH 
of 6.5 and a weak affinity for this homeostasis is 
particularly important because a low level of 
2'deoxyadenosine is essential for a proper function in 
immune cells. ADA1 has an optimal 
2'deoxyadenosine, these features make ADA2 
inefficient in deamination 2'deoxyadenosine in 
biological sites [30-32]. 
However, prognosis and outcome of acute 
hepatitis B infection are variable. As a result of 
subclinical infection, 
Chronic infection occurs frequently in 10% of 
infected individuals. In general, it is believed that 
immune system mediated processes play roles in the 
pathogenesis of hepatitis B infection. The 
mechanisms involved in liver cell injury may be an 
HLA class I restricted cytotoxic T-cell response 
directed at HBcAg/HBeAg on HBV- infected 
hepatocytes, direct cytopathic effect of HBcAg 
expression in infected hepatocytes in hepatitis, a 
direct toxic effect of HBV on liver cells, liver cell 
injury results from high-level expression and 
inefficient secretion of HBsAg, and finally co-
infection with a second cytopathic virus, the hepatitis 
delta virus (HDV) [9]. 
In summary, we believe ADA activity may be 
considered as a more efficient marker of hepatitis in 
comparison with healthy. Subsequently, we suggest 
that serum ADA activity and molecular weight can 
be used in the diagnosis of HBV patient as a 
supportive laboratory test in combination with the 
other clinical and laboratory findings.  
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